Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
4 minute read

AstraZeneca and Daiichi Sankyo Announced ENHERTU Met the Primary Endpoint of Progression-free Survival in Patients With Hr-positive Disease, Reducing the Risk of Disease Progression or Death by 49% Vs. Chemotherapy in Data Presented at ASCO

By Charles Gross
Today, 10:27 PM
Detailed positive results from the pivotal DESTINY-Breast04 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated superior and clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients with HER2-low (immunohistochemistry (IHC) 1+ or IHC 2+/in-situ hybridization (ISH)-negative) unresectable and/or metastatic breast c

AZN

Read More
2 minute read

AstraZeneca’s Covid-19 Vaccine, Vaxzevria Has Been Granted Approval in the European Union by the European Medicine Agency as a Third Dose Booster in Adults.

By Charles Gross
Today, 10:27 PM
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults. Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine schedule of either Vaxzevria or an EU-approved mRNA COVID-19 vaccine.

AZN

Read More
1 minute read

White House Says Currently No Plans To Share COVID-19 Shots With North Korea Battling Outbreak

By Vandana Singh
Today, 10:27 PM
The Biden administration says it currently has no plans to share COVID-19 vaccines with North Korea, Reuters reported citing White House press secretary Jen Psaki. However, it supported providing aid to North Korea. North Korea reported its first COVID-19 outbreak, calling it the "gravest national emergency" and ordering a national lockdown.

AZN

Read More
2 minute read

AstraZeneca Announced New Nirsevimab Data Analyses Reinforce Efficacy Against RSV

By Charles Gross
Today, 10:27 PM
Results from a prespecified pooled analysis of the pivotal MELODY Phase III and Phase IIb trials showed AstraZeneca and Sanofi's nirsevimab demonstrated an efficacy (relative risk reduction versus placebo) of 79.5% (95% Confidence Interval [CI] 65.9 to 87.7; P<0.0001) against medically attended lower respiratory tract infections (LRTI), such as bronchiolitis or pneumonia, caused by respiratory syn

AZN

Read More
2 minute read

AstraZeneca Announced Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults With Neuromyelitis Optica Spectrum Disorder

By Charles Gross
Today, 10:27 PM
Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris (ravulizumab-cwvz) achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) compared to the external placebo arm from the pivotal Soliris PREVENT clin

AZN